Peruvian congress approves legalization of medicinal pot

Peru's congress late Thursday overwhelmingly approved a measure supported by President Pedro Pablo Kuczynski that legalizes marijuana for medicinal use.

The proposal at first was controversial because of the thriving illegal drug trade: Peru is the world's second largest producer of coca leaves - the source plant for cocaine - and some worried that drug gangs would branch into the marijuana business.

Proponents emphasized however that the measure is aimed at extracting components from marijuana to address specific ailments.

The Kuczynski administration proposed legalizing medicinal marijuana in February, after police busted a home lab and arrested a group of parents who were distilling cannabis oil for children ill with cancer and severe cases of epilepsy.

The head of Peru's single chamber congress, Luis Galarreta, wrote on Twitter just before midnight that lawmakers voted mindful of "those people who need it for their treatment."

Pro-government lawmaker Alberto de Belaunde said that all charges should be dropped against the parents.

"Science is on our side, the regional current is on our side. Let's not let our fears paralyze us," he said ahead of the vote.

In 2013 Uruguay became the first country in the world to legalize pot from production to sale. The is sold only to people who have officially registered with a licensed pharmacy, and with a monthly limit of 40 grams.

Mexico, Colombia, Chile and Argentina have since authorized the cultivation and consumption of for medicinal and scientific purposes.


Explore further

Argentine Congress votes to legalize medical marijuana

© 2017 AFP

Citation: Peruvian congress approves legalization of medicinal pot (2017, October 20) retrieved 24 April 2019 from https://medicalxpress.com/news/2017-10-peruvian-congress-legalization-medicinal-pot.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
290 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more